Bevacizumab vedotin
Based on 1 Customer Validation
Bevacizumab vedotin is an antibody-drug conjugate (ADC). Bevacizumab vedotin blocks the VEGF/VEGFR pathway to exert anti-angiogenic effects. Bevacizumab vedotin exhibits anti-proliferative effects on cancer cells, promotes cancer cell apoptosis (Apoptosis), induces cancer cell cycle arrest, and possesses anti-migratory activity against breast cancer cells. Bevacizumab vedotin can be used in research related to glioma, hepatocellular carcinoma, and breast cancer.
For research use only. We do not sell to patients.
- Purity: 97.72%
- Molecular Weight:149114 (average)
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All VEGFR Isoforms
More
Biological Activity
Bevacizumab vedotin (1 mg; 72-120 h) exhibits high serum stability[1].
Bevacizumab vedotin (30-165 min) rapidly and completely releases its MMAE payload under the mediation of cathepsin B[1].
Bevacizumab vedotin (0-10 μg/mL; 48 h) potently inhibits the proliferation of U87, HepG2 and MCF-7 cells, with IC50 values of 14.1712 μg/mL, 0.6483 μg/mL and 0.1442 μg/mL, respectively[1].
Bevacizumab vedotin (1 μg/mL; 48 h) induces apoptosis in U87, HepG2 and MCF-7 cells after 48 h of treatment[1].
Treatment with Bevacizumab vedotin (0.1-20 μg/mL; 48 h) induces G1-phase cell cycle arrest in U87 and HepG2 cells[1].
Bevacizumab vedotin (0.01-0.1 μg/mL; 12-48 h) inhibits the migration of MCF-7 cells in a concentration- and time-dependent manner, and downregulates the expression of VEGF-A in MCF-7 cells[1].
Bevacizumab vedotin (0.1-1 μg/mL; 4-48 h) exhibits anti-angiogenic activity, reduces tube formation (junctions and branches) in HUVECs, downregulates VEGF-A expression, and upregulates VEGFR-2 expression in HUVECs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U87 , HepG2 , MCF-7 cells
-
Concentration:0, 0.01, 0.05, 0.1, 0.2, 0.5, 1, 5, 10 μg/mL
-
Incubation Time:48 h
-
Result:Inhibited proliferation of all three cell lines.
Reached an IC50 of 14.1712 μg/mL for U87 cells.
Reached an IC50 of 0.6483 μg/mL for HepG2 cells.
Reached an IC50 of 0.1442 μg/mL for MCF-7 cells.
-
Cell Line:U87 , HepG2 , MCF-7 cells
-
Concentration:1 μg/mL
-
Incubation Time:48 h
-
Result:Promoted apoptosis in all three cell lines.
Achieved a pro-apoptotic rate of 113% relative to the control group for U87 cells.
Achieved a pro-apoptotic rate of 304% relative to the control group for HepG2 cells.
Achieved a pro-apoptotic rate of 288% relative to the control group for MCF-7 cells.
-
Cell Line:U87 , HepG2 cells
-
Concentration:0.1-20 μg/mL
-
Incubation Time:48 h
-
Result:Induced G1 phase cell cycle arrest in U87 and HepG2 cells.
-
Cell Line:MCF-7 cells
-
Concentration:0, 0.01, 0.02, 0.05, 0.1 μg/mL
-
Incubation Time:0 h, 12 h, 24 h, 36 h and 48 h
-
Result:Enhanced concentration-dependent inhibition of MCF-7 cell migration with increasing incubation time.
-
Cell Line:MCF-7 cells
-
Concentration:0.01, 0.05, 0.1 μg/mL
-
Incubation Time:48 h
-
Result:Caused concentration-dependent downregulation of VEGF-A expression in MCF-7 cells.
-
Cell Line:HUVEC cells
-
Concentration:0.1, 0.5, 1 μg/mL
-
Incubation Time:48 h
-
Result:Caused concentration-dependent downregulation of VEGF-A expression in HUVEC cells.
Caused concentration-dependent upregulation of VEGFR-2 expression in HUVEC cells.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 149114 (average)
-
Color Colorless to light yellow
-
SMILES
[Bevacizumab vedotin]
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bevacizumab vedotin Related Classifications
HY-185208 Related Classifications
Powered by Bioz